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LETTERS TO THE EDITOR
TTF-1 Positivity in Mer-
kel Cell Carcinoma: The
Chosen Clone Matters
To the Editor:
I have read with great interest the
recently published article by Hughes
et al1 describing a case of a combined
Merkel cell carcinoma associated with
Bowen disease and squamous cell car-
cinoma that demonstrated strong and
signiﬁcant positivity for TTF-1 by
immunohistochemistry, and I would
like to make some additional com-
ments. The authors used in this case
study the monoclonal anti-TTF-1 anti-
body clone SP141 and did not explore
the possible difference between the
SP141 clone (Ventana) and the other
main available anti-TTF-1 antibody
clones, such as 8G7G31 (Dako) and
SPT24 (Leica/Novocastra). Moreover,
other published cases and case series
of (combined) MCC with TTF-1 posi-
tivity did not mention which type of
TTF-1 clone was used.2–4 However,
there is strong evidence in the litera-
ture that an important factor inﬂuenc-
ing the prevalence of TTF-1
expression in tumors is the type of
clone that is used.5,6 This has also been
demonstrated in publications docu-
menting TTF-1 immunoreactivity in
glial neoplasms,7 schwannomas,8
breast carcinomas,6 and colorectal car-
cinomas.9 I want to illustrate this mat-
ter further with a recent case of
a classical Merkel cell carcinoma,
clinically presenting as a rapidly grow-
ing, ﬁrm, solitary nodule in the face of
an 82-year-old woman. Histology
showed a dermal-based lesion com-
posed of monotonous small round cells
with ﬁnely granular and dusty chroma-
tin, inconspicuous nucleoli, and scanty
cytoplasm (“small blue round cell”
morphology). A membranous and par-
anuclear dot-like staining with cyto-
keratin 20 was observed. The tumor
cells showed diffuse cytoplasmic
staining with the neuroendocrine
markers chromogranin and synapto-
physin. The case was sent to me in
consultation, given the strong expres-
sion with the TTF-1 antibody clones
SP141 and SPT24 (Figs. 1A, B). Based
on my ﬁndings in the recent published
study on TTF-1 expression in schwan-
nomas,8 I performed an additional
monoclonal anti-TTF-1 antibody clone
8G7G31 (Dako) on this peculiar case,
which showed no expression (Fig. 1C).
The difference in speciﬁcity according
to the used anti-TTF-1 antibodies
could be explained by a higher afﬁnity
of SP141 and SPT24 clones for TTF-1,
which aberrantly expressed with a low
level in Merkel cell carcinoma that it
could not be detected by 8G7G31
clone. Other potential factors that can
explain the difference include method-
ological issues such as antibody dilu-
tions, antigen retrieval, and detection
systems. This case further underscores
the literature data that the sensitivity
and speciﬁcity of TTF-1 staining is
dependent on the antibody clone used,
and attention should be given on using
different clones of antibody raised
against the same protein for diagnostic
purpose.
David Creytens, MD, PhD
Department of Pathology, Ghent University
and Ghent University Hospital
Ghent, Belgium
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FIGURE 1. A, Hematoxylin and eosin staining of classical Merkel cell carcinoma (original magnification ·200). B, Strong nuclear
TTF-1 positivity (clone SP141; original magnification ·200). C, No TTF-1 reactivity (clone 8G7G31; original magnification ·200).
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